Azacitidine Treatment "Significantly Extends Overall Survival" For Myelodysplastic Syndromes and Acute Myeloid Leukemia Patients

Posted on June 21, 2009 by David Austin

This article discusses recent studies on the success of azacitidine (Vidaza®) treatment in reducing transfusion dependency, and increasing overall survival in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) patients.

Data presented at the 14th Congress of the European Society of Hematology demonstrate that treatment with azacitidine (Vidaza®) significantly extends overall survival and helps patients with myelodysplastic syndromes (MDS) become or remain red blood cell transfusion independent. Patients who benefited included those with higher-risk MDS or acute myeloid leukaemia (AML) with 20-30% blasts, as defined by the World Health Organization (WHO).
“The presentations at EHA this year continue to support the clinical benefit associated with Vidaza in MDS, including significantly extended overall survival...

Read the full article at ecancermedicalscience.com.

 

 

Tags: , , , , , ,
Trackbacks (0) Links to blogs that reference this article Trackback URL
http://www.benzeneleukemialawblog.com/admin/trackback/140694
Comments (0) Read through and enter the discussion with the form at the end
Post A Comment / Question Use this form to add a comment to this entry.







Remember personal info?
Send To A Friend Use this form to send this entry to a friend via email.